Crown Bioscience Inc., THE JACKSON LABORATORY, Champions Oncology, Inc. are Dominating the Global PDX Models Market in 2019

Global PDX Models Market is expected to grow with the CAGR of 16.6% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access full Report @ https://www.databridgemarketresearch.com/reports/global-pdx-models-market

Global PDX models market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in global PDX models market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in September 2018, Crown Bioscience Inc. announced the launch of the new PDX models of prostate cancer and provided a next level platform in the advance oncology. This has provided relevant solutions and at the same time it also helped in broadening of the product portfolio.  

Crown Bioscience Inc. is the dominating player in global PDX models market. The other key players existing in the market includes THE JACKSON LABORATORY, Champions Oncology, Inc., Charles River Laboratories, Wuxi AppTec, Oncodesign, Aragen Bioscience, Biocytogen, Bioduro, BioModels, Creative Animodel, Covance Inc., EPO Berlin-Buch GmbH, EUROPDX., Explora BioLabs, Hera BioLabs, Horizon discovery Ltd., Pharmatest Services, Urospehere SAS, Xentech, Xenopat among others.

Crown Bioscience Inc.:   

Crown Bioscience Inc. was headquartered in California, U.S. The company focuses on providing services which includes preclinical, translational, predictive models, biomarker delivery among others. The company deals in various product categories such as CVMD, oncology, inflammation, models among which oncology is the market focused category. The company is engaged in continuous development of PDX models market. 

For instance,

  • In April 2020, Crown Bioscience Inc. acquired unique models from Leading Academic Medical Centres, the company made an agreement with Dana-Farber Cancer Institute and University of Washington. This helps in the product expansion of the company and provides a support to the oncology drug development community.

The company has wide presence across North America, Europe, China and Taiwan.

THE JACKSON LABORATORY

THE JACKSON LABORATORY, headquartered in Marine, U.S. was founded in 1929. The company focuses on providing techniques, software, scientific resources, cryopreservation, tissues, and recovery cells. The company deals in various product categories such as solutions by therapeutic area, model generation, breeding & rederivation, in vivo pharmacology, cryo & strain donation & clinical services among which in vivo pharmacology is the market focused category. The company is engaged in continuous development of PDX models market. 

For instance,

  • In April 2018, THE JACKSON LABORATORY and European Bioinformatics Institute created first cancer research portal for PDX models. By using these models researchers can understand better drug reaction on the patient which is patient specific too. This has provided wide variety of the models at one place quickly.  

The company has wide presence across the U.S. and China.

Champions Oncology, Inc.:

Champions Oncology, Inc. headquartered in New Jersey, U.S. was founded in 2007. The company is engaged in focused on developing oncology products and provides clinical trials and solutions. The company has business segment namely oncology services. The company deals in various product categories such as preclinical testing platforms, translational research & clinical trial solutions among which translational research is the market focused category. The company is engaged in continuous development of PDX models market.   

For instance,

  • In June 2018, Champions Oncology, Inc. announced their partnership with Puma Biotechnology and NSABP Foundation, Inc. for the development of patient derived xenograft models in two multi center co-clinical trials. This partnership could be advancement for understanding the sensitivity of cancers. Hence, leading more efficient in providing services to the customers in the segment.

The company has wide presence across the U.S., U.K., China and Taiwan. The company also has its subsidiary named as champions Biotechnology U.K. Ltd. (U.K.).